Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Published:2022-01 Issue:1 Volume:23 Page:77-90
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yau Thomas,Park Joong-Won,Finn Richard S,Cheng Ann-Lii,Mathurin Philippe,Edeline Julien,Kudo Masatoshi,Harding James J,Merle Philippe,Rosmorduc Olivier,Wyrwicz Lucjan,Schott Eckart,Choo Su Pin,Kelley Robin Kate,Sieghart Wolfgang,Assenat Eric,Zaucha Renata,Furuse Junji,Abou-Alfa Ghassan K,El-Khoueiry Anthony B,Melero Ignacio,Begic Damir,Chen Gong,Neely Jaclyn,Wisniewski Tami,Tschaika Marina,Sangro Bruno

Funder

Ono Pharmaceutical Co Ltd

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2016

3. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018

4. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib;Reig;J Hepatol,2014

5. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

Cited by 689 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Immunotherapy for hepatocellular carcinoma;JHEP Reports;2024-10

3. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

4. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

5. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11